08 October 2018, Geneva, Switzerland: On 17 September, 2018, Prof. Philip Newsome was unanimously nominated to the position of EASL Vice-Secretary, taking over from Prof. Frank Tacke who stepped down from this position in order to pursue new academic challenges.
A new study found a web-based intervention to be an effective and convenient approach to manage lifestyle changes in patients with NAFLD, reports the Journal of Hepatology.
Geneva, Switzerland, 20 September 2018 - The EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit commenced today at the Starling Hotel Conference Centre in Geneva, Switzerland, attended by over 300 basic and clinical researchers, industry, and renowned specialists from around the world.
Physicians and researchers have noted the increase in liver disease over the last couple decades, especially nonalcoholic fatty liver disease, correlates significantly with the increase in obesity and overweight.
Research reveals that an existing drug used to treat liver disease could also be employed in Alzheimer's disease therapy. The drug "heals" malfunctioning elements at cellular level.
Professor Jan De Groote recently passed away aged 93. He will be remembered as the first Secretary General of EASL (1966–1969) and as one of the founding fathers of “the Gnomes”, the International Liver Pathology Study Group.
Photo caption: Dr. Anatolij Horuzsko, reproductive immunologist in the Georgia Cancer Center and Department of Medicine at the Medical College of Georgia at Augusta University (photo credit: Phil Jones, Senior Photographer, Augusta University) Problems like obesity and alcoholism appear to…
Increasing the amount of protein in the diet may reduce the liver's fat content and lower the risk of diabetes in people with nonalcoholic fatty liver disease (NAFLD). The study is published ahead of print in the American Journal of…
(Reuters Health) - People who have fatty liver disease that wasn’t caused by heavy drinking may still need to avoid alcohol if they want to prevent their liver damage from getting worse, a Korean study suggests.
Researchers from many international institutions have teamed up to design a more effective drug for liver cancer therapy. Their compound may help improve survival rates and reduce adverse effects.